Literature DB >> 24266637

Adherence and patients' experiences with the use of oral anticancer agents.

Lonneke Timmers1, Christel C L M Boons, Femke Kropff, Peter M van de Ven, Eleonora L Swart, Egbert F Smit, Sonja Zweegman, Judith R Kroep, Johanna N H Timmer-Bonte, Epie Boven, Jacqueline G Hugtenburg.   

Abstract

A rapidly growing number of oral anticancer agents has become available in oncology and hematology. Though these introductions have several benefits, medication adherence is an issue of concern. Little is known about the factors influencing adherence to treatment with oral anticancer agents in daily practice. Material and methods. In this observational, multicenter study including 216 patients, carried out between October 2010 and March 2012, the use of oral anticancer drugs was assessed by means of a telephonic pill count, a questionnaire and a review of the patient's medical file and pharmacy medication records. Parameters collected were patients' demographics, treatment characteristics, beliefs and attitude towards disease and medicines, self-reported adherence, side effects, quality of life and satisfaction about information. Patients off treatment filled out a questionnaire about the reasons for discontinuation. Optimal adherence was defined as ≥ 95%-≤ 105%. Results. The mean adherence rate (AR) (n = 177) was 99.1% with 20.3% of patients having a sub-optimal AR (< 95%, > 105%) consisting both of under- and over-adherence. Multivariate analyses showed that being on a cyclic dosing regimen (rather than a continuous regimen), not living alone and being highly educated increased the chances of optimal adherence (ORs = 4.88, 4.59 and 2.53, respectively). In addition, optimal adherence was found to be less common in patients reporting treatment control (OR = 0.77). One third of 79 patients off treatment reported their experienced side effects as one of the reasons for discontinuation. Discussion. Although most patients are fully adherent to oral anticancer agents, there is a substantial number tending to non-adherence. Patients living alone and those on a continuous dosing regimen are most likely to adhere sub-optimally. Interventions to improve adherence should specifically address these patients and be tailored to the needs of the individual patient.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24266637     DOI: 10.3109/0284186X.2013.844353

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  21 in total

1.  Challenges to the design and testing supportive interventions for cancer patients treated with oral oncolytic agents.

Authors:  Charles W Given; Barbara A Given; Alla Sikorskii; John C Krauss; Eric Vachon
Journal:  Support Care Cancer       Date:  2018-08-23       Impact factor: 3.603

2.  Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.

Authors:  Hira Mian; Mark Fiala; Tanya M Wildes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-10-09

3.  High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany.

Authors:  Stefan Feiten; Geothy Chakupurakal; Hans Peter Feustel; Michael Maasberg; Burkhard Otremba; Peter Ehscheidt; Manfred Hensel; Richard Hansen; Rudolf Weide
Journal:  Support Care Cancer       Date:  2019-03-11       Impact factor: 3.603

4.  Influence of the COVID-19 Pandemic on Adherence to Orally Administered Antineoplastics.

Authors:  Amparo Talens; Elsa López-Pintor; Marta Bejerano; Mercedes Guilabert; María Teresa Aznar; Ignacio Aznar-Lou; Blanca Lumbreras
Journal:  J Clin Med       Date:  2022-04-26       Impact factor: 4.964

Review 5.  Oral antineoplastic agents: how do we care about adherence?

Authors:  Marie Barillet; Virginie Prevost; Florence Joly; Bénédicte Clarisse
Journal:  Br J Clin Pharmacol       Date:  2015-10-28       Impact factor: 4.335

Review 6.  The Association Between Patient-Reported and Objective Oral Anticancer Medication Adherence Measures: A Systematic Review
.

Authors:  Thomas M Atkinson; Vivian M Rodríguez; Mallorie Gordon; Isabelle K Avildsen; Jessica C Emanu; Sarah T Jewell; Kimberly A Anselmi; Pamela K Ginex
Journal:  Oncol Nurs Forum       Date:  2016-09-01       Impact factor: 2.172

7.  Patients' Perceived Continuity of Care and Adherence to Oral Anticancer Therapy: a Prospective Cohort Mediation Study.

Authors:  Orit Cohen Castel; Efrat Dagan; Lital Keinan-Boker; Marcelo Low; Efrat Shadmi
Journal:  J Gen Intern Med       Date:  2021-03-25       Impact factor: 6.473

8.  Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil.

Authors:  Monica Napoleão Fortes Rego; Konradin Metze; Irene Lorand-Metze
Journal:  Clinics (Sao Paulo)       Date:  2015-05-01       Impact factor: 2.365

9.  Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.

Authors:  Lonneke Timmers; Christel C L M Boons; J Moes-Ten Hove; Egbert F Smit; Peter M van de Ven; Joachim G Aerts; Eleonora L Swart; Epie Boven; Jacqueline G Hugtenburg
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-06       Impact factor: 4.553

10.  Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study.

Authors:  Christine Leong; Piotr Czaykowski; Marc Geirnaert; Alan Katz; Roxana Dragan; Marina Yogendran; Colette Raymond
Journal:  Can J Public Health       Date:  2021-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.